Literature DB >> 17442220

The metabolic syndrome in primary aldosteronism.

Francesco Fallo1, Giovanni Federspil, Franco Veglio, Paolo Mulatero.   

Abstract

Patients with hypertension have a high prevalence of concurrent metabolic abnormalities (eg, obesity, dyslipidemia, and hyperglycemia). Clustering of these risk factors, defined as the metabolic syndrome, is associated with a high cardiovascular risk profile. This review summarizes current knowledge about the prevalence and characteristics of the metabolic syndrome in primary aldosteronism, and discusses the possible pathophysiological link between aldosterone and individual components of the metabolic syndrome, other than hypertension. Impaired glucose metabolism due to insulin resistance appears to be the major contributor to metabolic dysfunction in primary aldosteronism. Experimental observations support the possibility that aldosterone could act directly on insulin receptor function. The potential proadipogenic role of aldosterone and its negative effect on insulin sensitivity through production of cytokines remains to be investigated. Higher rates of cardiovascular events reported in primary aldosteronism could be due in part to the increased prevalence of the metabolic syndrome in this disorder.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17442220     DOI: 10.1007/s11906-007-0019-1

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   4.592


  49 in total

1.  Report of the expert committee on the diagnosis and classification of diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2003-01       Impact factor: 19.112

Review 2.  Aldosterone as a cardiovascular risk factor.

Authors:  GianPaolo Rossi; Marco Boscaro; Vanessa Ronconi; John W Funder
Journal:  Trends Endocrinol Metab       Date:  2005-04       Impact factor: 12.015

3.  Can primary hyperaldosteronism be considered as a specific form of diabetes mellitus?

Authors:  J Widimský; B Strauch; G Sindelka; J Skrha
Journal:  Physiol Res       Date:  2001       Impact factor: 1.881

4.  Hypertension, the potassium ion and impaired carbohydrate tolerance.

Authors:  J W Conn
Journal:  N Engl J Med       Date:  1965-11-18       Impact factor: 91.245

Review 5.  Syndrome X: 6 years later.

Authors:  G M Reaven
Journal:  J Intern Med Suppl       Date:  1994

6.  Cardiovascular risk profile and blood pressure control in Italian hypertensive patients under specialist care.

Authors:  Giuseppe Mancia; Roberto Volpe; Stefano Boros; Maura Ilardi; Cristina Giannattasio
Journal:  J Hypertens       Date:  2004-01       Impact factor: 4.844

7.  Effect of adrenal steroids on insulin release from cultured rat islets of Langerhans.

Authors:  J Pierluissi; F O Navas; S J Ashcroft
Journal:  Diabetologia       Date:  1986-02       Impact factor: 10.122

8.  Insulin resistance in secondary hypertension.

Authors:  A Shamiss; J Carroll; T Rosenthal
Journal:  Am J Hypertens       Date:  1992-01       Impact factor: 2.689

9.  Insulin resistance in essential hypertension.

Authors:  E Ferrannini; G Buzzigoli; R Bonadonna; M A Giorico; M Oleggini; L Graziadei; R Pedrinelli; L Brandi; S Bevilacqua
Journal:  N Engl J Med       Date:  1987-08-06       Impact factor: 91.245

Review 10.  The new biology of aldosterone.

Authors:  John M C Connell; Eleanor Davies
Journal:  J Endocrinol       Date:  2005-07       Impact factor: 4.286

View more
  9 in total

Review 1.  Primary aldosteronism.

Authors:  Richard J Auchus; Fiemu E Nwariaku
Journal:  Curr Cardiol Rep       Date:  2007-11       Impact factor: 2.931

Review 2.  Adrenal steroids and the metabolic syndrome.

Authors:  Stephen P Thomson; Craig S Stump; L Romayne Kurukulasuriya; James R Sowers
Journal:  Curr Hypertens Rep       Date:  2007-12       Impact factor: 5.369

Review 3.  Central regulation of blood pressure by the mineralocorticoid receptor.

Authors:  Elise P Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Mol Cell Endocrinol       Date:  2011-06-01       Impact factor: 4.102

4.  Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome.

Authors:  Melvin R Hayden; James R Sowers
Journal:  J Am Soc Hypertens       Date:  2008-06-02

Review 5.  Hyperaldosteronism: Screening and Diagnostic Tests.

Authors:  Chiara Sabbadin; Francesco Fallo
Journal:  High Blood Press Cardiovasc Prev       Date:  2016-03-14

6.  Aldosterone and hypertension in the cardiometabolic syndrome.

Authors:  Sameer Stas; Adam T Whaley-Connell; James R Sowers
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-02       Impact factor: 3.738

7.  Role of the Renin-Angiotensin system and aldosterone on cardiometabolic syndrome.

Authors:  P Stiefel; A J Vallejo-Vaz; S García Morillo; J Villar
Journal:  Int J Hypertens       Date:  2011-06-23       Impact factor: 2.420

Review 8.  Who should be screened for primary aldosteronism? A comprehensive review of current evidence.

Authors:  Wei-Chieh Huang; Yen-Hung Lin; Vin-Cent Wu; Chen-Huan Chen; Saulat Siddique; Yook-Chin Chia; Jam Chin Tay; Guruprasad Sogunuru; Hao-Min Cheng; Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-09       Impact factor: 2.885

9.  Independent Association of Serum Aldosterone Level with Metabolic Syndrome and Insulin Resistance in Korean Adults.

Authors:  Se Hee Min; Se Hong Kim; In Kyung Jeong; Ho Chan Cho; Jin Ok Jeong; Ju Hee Lee; Hyun Jae Kang; Hyo Soo Kim; Kyong Soo Park; Soo Lim
Journal:  Korean Circ J       Date:  2018-03       Impact factor: 3.243

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.